Carles Escriu

3.3k total citations · 1 hit paper
29 papers, 1.9k citations indexed

About

Carles Escriu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Carles Escriu has authored 29 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Carles Escriu's work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Carles Escriu is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Carles Escriu collaborates with scholars based in United Kingdom, United States and Italy. Carles Escriu's co-authors include Pieter E. Postmus, Solange Peters, Matthijs Oudkerk, Keith M. Kerr, David Waller, Suresh Senan, Johan Vansteenkiste, Aaron M. Gruver, John R. Gosney and John K. Field and has published in prestigious journals such as Journal of Clinical Oncology, Nature Cell Biology and International Journal of Molecular Sciences.

In The Last Decade

Carles Escriu

24 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 1.5k citations Pieter E. Postmus, Keith M. Kerr et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Carles Escriu

Since Specialization

Citations

This map shows the geographic impact of Carles Escriu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carles Escriu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carles Escriu more than expected).

Fields of papers citing papers by Carles Escriu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carles Escriu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carles Escriu. The network helps show where Carles Escriu may publish in the future.

Co-authorship network of co-authors of Carles Escriu

This figure shows the co-authorship network connecting the top 25 collaborators of Carles Escriu. A scholar is included among the top collaborators of Carles Escriu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carles Escriu. Carles Escriu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	OA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC 2025 ·Journal of Thoracic Oncology ·Collin M. Blakely, Jacqulyne Robichaux, (unknown), (unknown), Kyung‐Yul Lee, Nguyen Viet Nhung, (unknown), Jamie E. Chaft, Jiaxi He, W. Weder, (unknown), (unknown), Carles Escriu, (unknown), Preetida J. Bhetariya, Bala Swaminathan, Yuri Rukazenkov, (unknown), Maximilian J. Hochmair	1
2	Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations 2024 ·Cancers ·(unknown), (unknown), Helen Wong, (unknown), (unknown), Sarah Rose, (unknown), Carles Escriu	1
3	Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England 2024 ·Clinical Lung Cancer ·(unknown), (unknown), (unknown), Shobhit Baijal, Pallav Bhatnagar, K. Clarke, Carles Escriu, (unknown), K. Franks, Joshil Lodhia, Marco Nardini, (unknown), Michael Shackcloth	0
4	117 Prognostic factors for 90-day acute care outcomes in lung cancer patients 70 and over 2024 ·Lung Cancer ·D. Cobben, Bridget A. Taylor, Helen Wong, Carles Escriu	0
5	Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis 2024 ·Therapeutic Advances in Medical Oncology ·(unknown), (unknown), Carles Escriu, (unknown), Riyaz Shah, (unknown), Samantha Cox, (unknown), Emilio Bria, (unknown), (unknown), Toby Talbot, Rita Leporati, K. Balachandran, Tom Newsom‐Davis, Sarah Hughes, Laura Cove-Smith, Paul Taylor, Fiona Blackhall, Raffaele Califano	1
6	Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis 2023 ·Frontiers in Oncology ·(unknown), (unknown), Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, David J. Pinato, Christian H. Ottensmeier, Sara Campos, S. Muthuramalingam, Samuel H.H. Chan, Fábio Gomes, Giuseppe Luigi Banna	6
7	Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis 2023 ·Journal of Thoracic Oncology ·Conor S. Gillespie, (unknown), (unknown), (unknown), Keng Siang Lee, David M. Hughes, Carles Escriu, Rasheed Zakaria	43
8	The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, (unknown), David J. Pinato, Christian H. Ottensmeier, Fábio Gomes, Giuseppe Luigi Banna	3
9	DO GENOMIC ALTERATIONS INflUENCE THE DEVELOPMENT OF BRAIN METASTASES IN ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER? A SYSTEMATIC REVIEW AND META-ANALYSIS 2023 ·Neuro-Oncology ·Conor S. Gillespie, (unknown), (unknown), (unknown), Keng Siang Lee, David M. Hughes, Carles Escriu, Rasheed Zakaria	1
10	Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study 2022 ·International Immunopharmacology ·Giuseppe Luigi Banna, Ornella Cantale, S. Muthuramalingam, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Alessio Signori, Hayley McKenzie, Carles Escriu, Gloria Barone, (unknown), Alexander Hicks, (unknown), David J. Pinato, Christian H. Ottensmeier, Fábio Gomes	21
11	Role and evidence for targeted therapies in surgically resectable non-small cell lung cancer: a narrative review 2022 ·Carles Escriu	1
12	Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom 2021 ·BMC Cancer ·J.F. Lester, Carles Escriu, Sarah Khan, Emma Hudson, T. Mansy, (unknown), (unknown), Ceri Powell, Juliet Brock, John Conibear, (unknown), (unknown), Xiaohui Zhuo, (unknown), (unknown), Peter Martin, Xinke Zhang, Vivek Pawar	19
13	Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG) 2021 ·Lung Cancer ·Sanjay Popat, Hyun Ae Jung, Shin Yup Lee, Maximilian J. Hochmair, Seung Hyeun Lee, Carles Escriu, Min Ki Lee, Maria Rita Migliorino, Yong Chul Lee, Nicolas Girard, (unknown), Angela Märten, Satoru Miura	19
14	1223P Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG) 2021 ·Annals of Oncology ·Sanjay Popat, Hyun Ae Jung, (unknown), Maximilian J. Hochmair, Seung Hyeun Lee, Carles Escriu, (unknown), M.R. Migliorino, (unknown), Nicolas Girard, (unknown), Angela Märten, Satoru Miura	1
15	Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA 2021 ·Future Oncology ·Masahiro Tsuboi, Walter Weder, Carles Escriu, Collin M. Blakely, Jianxing He, Sanja Đačić, Yasushi Yatabe, Lingmin Zeng, Andrew Walding, Jamie E. Chaft	106
16	1379P Real-world (RW) clinical outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom 2020 ·Annals of Oncology ·J. Lester, Carles Escriu, Sabbir Khan, (unknown), T. Mansy, (unknown), Siu Yuen Chan, Charles S. Powell, (unknown), John Conibear, (unknown), (unknown), Xianlu Zhuo, (unknown), (unknown), Philip Martin, (unknown), (unknown)	2
17	Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response 2019 ·Lung Cancer ·(unknown), John K. Field, Michael P.A. Davies, Carles Escriu, Aaron M. Gruver, John R. Gosney	124
18	Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network 2019 ·BMC Pulmonary Medicine ·(unknown), Helen Wong, Carles Escriu	7
19	Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up breakdown → 2017 ·Annals of Oncology ·Pieter E. Postmus, Keith M. Kerr, Matthijs Oudkerk, Suresh Senan, David Waller, Johan Vansteenkiste, Carles Escriu, Solange Peters	1455
20	Diverse epigenetic strategies interact to control epidermal differentiation 2012 ·Nature Cell Biology ·Klaas W. Mulder, Xin Wang, Carles Escriu, Yoko Itō, Roland F. Schwarz, Jesse Gillis, Gábor Sirokmány, Giacomo Donati, Santiago Uribe‐Lewis, Paul Pavlidis, Adele Murrell, Florian Markowetz, Fiona M. Watt	115

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact